Piper Sandler高级研究分析师杰西卡.塔桑(Jessica Tassan)表示，在充满挑战的联邦医疗保险优势计划 (Medicare Advantage)费率环境中，联合健康集团(UNH.US)是应对能力最强的公司，其核心原因包括公 司规模庞大的基础设施、深厚的基于价值的医疗业务底蕴，以及对联邦医疗保险这一核心业务的战略坚 守。 这一评估是在医疗保险和医疗补助服务中心(Centers for Medicare and Medicaid Services)发布2027年预估 费率通知后做出的。该通知显示，预计平均收入变化近乎持平，仅为0.09%，与2026年约5%的增幅相比 出现大幅下降。 据了解，由于当前医疗通胀率仍维持在较高水平，这一近乎持平的费率实际上构成了显著的盈利压力。 与此同时，政府计划通过严厉打击"虚增代码"行为来收紧预算，预计到2027年将导致整个保险行业减少 超过70亿美元的收入，这一政策导向直接触发了资本市场的剧烈抛售。 受此冲击，联合健康的股价在2026年1月27日遭遇重挫，跌幅一度接近20%，最终收跌19.61%，市值蒸 发规模创下历史记录。 在接受采访时，塔桑详细阐释了医疗保 ...

专题：聚焦美股2025年第四季度财报 美国联合健康集团于本周二发布 2026 年调整后利润预期，该数值略高于分析师此前的预估。这一信号 表明，公司首席执行官斯蒂芬・赫姆斯利推行的医疗成本管控措施已开始显现成效。 赫姆斯利于去年 5 月重返首席执行官岗位，肩负着重塑投资者与消费者对这家医疗健康巨头信任的重 任。此前，联合健康集团深陷多事之秋，不仅遭遇高管遇刺事件、医疗成本飙升、联邦政府调查等多重 危机，还因保险行业的相关操作引发美国民众的不满。赫姆斯利上任后，正致力于带领公司走出这一困 境。 联合健康集团原本计划在 2026 年实现业绩回升，但公司同时表示，面向美国低收入群体的医疗补助 （Medicaid）业务复苏之路充满挑战，根源在于医疗服务的报销标准与实际成本不匹配。此外，公司还 缩减了面向老年人的联邦医疗保险优势计划（Medicare Advantage）相关产品的供给。 责任编辑：郭明煜 专题：聚焦美股2025年第四季度财报 美国联邦政府于本周一公布提案，计划明年将私营保险公司运营的联邦医疗保险优势计划的报销比例平 均上调 0.09%，这一增幅远低于华尔街的预期。 受此消息影响，哈门那、西维斯健康、联合 ...

《华尔街曰报》周一援引美国参议院某委员会的调查报告称，健康保险巨头联合健康集团曾采用激进手 段收集患者诊断信息，以此抬高其联邦医疗保险优势计划的赔付金额。 在盘前交易中，该公司股价下跌 1.4%，报每股 339.42 美元。 《华尔街曰报》指出，这份参议院报告并未提出正式建议，也未指控联合健康集团存在不当行为。 对于路透社的置评请求，该公司暂未予回应。 《华尔街曰报》周一援引美国参议院某委员会的调查报告称，健康保险巨头联合健康集团曾采用激进手 段收集患者诊断信息，以此抬高其联邦医疗保险优势计划的赔付金额。 在盘前交易中，该公司股价下跌 1.4%，报每股 339.42 美元。 《华尔街曰报》指出，这份参议院报告并未提出正式建议，也未指控联合健康集团存在不当行为。 对于路透社的置评请求，该公司暂未予回应。 责任编辑：郭明煜 责任编辑：郭明煜 ...

Core Viewpoint - There is growing optimism in the market regarding UnitedHealth Group's performance improvement, as indicated by multiple Wall Street analysts raising their stock price targets ahead of the company's Q3 earnings report [1] Analyst Upgrades - Mizuho analyst Ann Hynes raised the target price from $300 to $430 while maintaining a "Buy" rating [1] - Barclays analyst Andrew Mok increased the target price from $352 to $386, also reaffirming a "Buy" rating [1] - Bernstein analyst Lance Wilkes raised the target price from $379 to $433 and confirmed a "Buy" rating [1] Stock Performance - Despite challenges such as high medical costs, a Department of Justice investigation, and the sudden departure of the CEO, the stock has rebounded over 7% in the past month [1] - Positive factors driving the recent recovery include Berkshire Hathaway's disclosure of its stake in the company [1] - The company reiterated its earnings guidance, and its "Medicare Advantage Plan" received favorable updates in star ratings [1]

Core Viewpoint - Despite nearing retirement, Buffett's ability to identify valuable investments remains strong, as evidenced by significant stock purchases in the second quarter by Berkshire Hathaway, particularly in UnitedHealth Group, which saw a notable pre-market surge of over 12% [1][4]. Group 1: UnitedHealth Group - UnitedHealth Group's stock price has experienced a dramatic decline of over 50% in the past 12 months, resulting in a market value loss of nearly $270 billion [4]. - The company is currently under investigation by the U.S. Department of Justice regarding its Medicare Advantage billing practices, with allegations of improper diagnosis coding to inflate patient risk scores for higher reimbursements [6]. - Following a series of scandals and disappointing earnings reports, UnitedHealth's management underwent significant changes, including the appointment of a new CEO after a 27% stock price drop in May [6][4]. - Buffett's Berkshire Hathaway acquired over 5 million shares of UnitedHealth in the second quarter, with a market value of approximately $1.57 billion at the end of the quarter [7]. Group 2: Other Stocks Purchased by Berkshire Hathaway - In addition to UnitedHealth, Berkshire Hathaway also made significant purchases in six other stocks during the second quarter, including Nucor Steel (over 6.6 million shares), Lennar (over 7 million shares), and D.R. Horton (148,500 shares) [10]. - The total market value of these new positions at the end of the second quarter was approximately $3.65 billion [10]. - Other stocks that saw price increases in the pre-market include Nucor Steel (over 7%), Lennar (over 6%), and D.R. Horton (over 5%) [10].

Group 1 - Despite nearing retirement, Buffett's investment prowess remains strong, as evidenced by significant stock purchases in the second quarter [1] - Berkshire Hathaway made substantial investments in six stocks during the second quarter, with UnitedHealth Group seeing a pre-market surge of over 12% [1][3] - UnitedHealth's stock price rebounded significantly after a series of scandals and a sharp decline, attracting attention from major investors [3][6] Group 2 - The U.S. Department of Justice is investigating UnitedHealth's billing practices related to Medicare Advantage, raising concerns about potential overbilling [5] - UnitedHealth has faced multiple challenges, including a recent lawsuit aimed at blocking its acquisition of Amedisys and disappointing quarterly earnings [5] - In the second quarter, Buffett acquired over 5 million shares of UnitedHealth, with a market value of approximately $1.57 billion at the end of the quarter [6] Group 3 - In addition to UnitedHealth, Berkshire's second-quarter investments included Nucor Steel, Lennar, D.R. Horton, Lamar Advertising, and Allegion, with a total market value of approximately $3.65 billion [8] - Berkshire also reduced its holdings in Apple and Bank of America, while increasing positions in Chevron and other companies [9]